Table 6B.
Model-adjusted means* (SEM) and corresponding P-values for health-related outcomes and ADG from Day 0 to closeout by treatment group for steers with a WS > 2.
| Parameter | Salinea | FTSa | TILa | TIL + FTSa | P-value FTSα | P-value TILβ | P-value TIL + FTSδ |
|---|---|---|---|---|---|---|---|
| BRD case-fatality (%) | 3.1 (1.4) | 3.4 (1.0) | 3.3 (1.0) | 1.5 (0.7) | 0.54 | 0.50 | 0.44 |
| Removals (%) | 5.3 (1.8) | 6.3 (1.4) | 1.8 (0.7) | 2.1 (0.8) | 0.66 | <0.01 | 0.95 |
| DNF (%)b | 8.8 (2.1) | 9.4 (1.6) | 5.0 (1.2) | 3.5 (1.0) | 0.68 | <0.01 | 0.31 |
| Adjusted-ADG (lbs/day)c | 3.3 (0.05) | 3.3 (0.03) | 3.3 (0.03) | 3.3 (0.03) | 0.94 | 0.11 | 0.79 |
Mixed models with a random effect to account for lack of independence among treatment groups within pens, and pens within 2 different sites.
Saline, negative control; FTS, Flunixin transdermal solution; TIL, tildipirosin; and TIL + FTS, concurrent administration of TIL and FTS.
DNF, did not finish; a combination of both calves that died or were removed due to BRD from Day 0-closeout of this study.
Adjusted-ADG: adjusted Average Daily Gain based on a 63% carcass yield.
P-values reflect the overall effect of FTS, TIL, and their interaction, respectively. P-values for each main effect reflect a model-adjusted average between treatments incorporating the product compared to those that do not. For example, the P-value for the FTS main effect reflects the comparison between treatments that implement FTS (i.e., FTS and TIL+FTS) vs. those that do not (i.e., Saline + TIL). Only when the P-value for the interaction is significant (P ≤ 0.05) are direct comparison made between the four treatment groups.
P-value for main effect of Flunixin transdermal solution.
P-value for main effect of tildipirosin.
P-value for interaction of tildipirosin and Flunixin transdermal solution.